|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
7.500 USD |
+112.46% | +101.07% | +54.00% | |
April 08, 2025 at 05:34 am EDT
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires – 2025
|
Bluejay Diagnostics Sinks Premarket Following Investor Agreement to Exercise Warrants at ‘Reduced’ Price |
05:34am |
MT |
|
Bluejay Diagnostics Announces Entry Into Warrant Inducement Transaction For Approximately $3.7 Million In Gross Proceeds |
Apr. 07 |
RE |
|
Top Premarket Gainers |
Apr. 07 |
MT |
|
Bluejay Diagnostics, Inc. Auditor Raises ‘Going Concern’ Doubt |
Mar. 30 |
CI |
|
Wall Street to Open Slightly Higher Friday as Payrolls Data Tops Forecasts |
Dec. 06 |
MT |
|
Wall Street Set to Open Flat Thursday; Initial Jobless Claims Higher Than Expected |
Dec. 05 |
MT |
|
Investors Await Jobless Claims Data as Markets Tread Water in Thursday’s Premarket |
Dec. 05 |
MT |
|
Bluejay Diagnostics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 |
Nov. 07 |
CI |
|
Certain Stock Option of Bluejay Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 26-SEP-2024. |
24-09-25 |
CI |
|
Certain Warrants of Bluejay Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 26-SEP-2024. |
24-09-25 |
CI |
|
Certain Common Stock of Bluejay Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 26-SEP-2024. |
24-09-25 |
CI |
|
Bluejay Diagnostics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 |
24-08-14 |
CI |
|
Bluejay Diagnostics Closes $8.8 Million Public Offering |
24-06-28 |
MT |
|
Top Midday Decliners |
24-06-27 |
MT |
|
Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data |
24-06-27 |
MT |
|
US Futures Trend Lower Pre-Bell as Investors Await Slew of Economic Data |
24-06-27 |
MT |
|
Buejay Diagnostics, Inc Announces Results from the Primary Analysis of SYMON-I |
24-06-26 |
CI |
|
Bluejay Diagnostics, Inc. announced a financing transaction |
24-05-30 |
CI |
|
Bluejay Diagnostics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 |
24-05-15 |
CI |
|
Bluejay Diagnostics, Inc. Appoints Neil Dey as Principal Financial and Accounting Officer |
24-04-02 |
CI |
|
Bluejay Diagnostics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 |
24-03-28 |
CI |
|
Bluejay Diagnostics, Inc. Auditor Raises ‘Going Concern’ Doubt |
24-03-27 |
CI |
|
Top Premarket Decliners |
23-12-28 |
MT |
|
Top Midday Decliners |
23-12-27 |
MT |
|
Bluejay Diagnostics Starts Clinical Study of Symphony IL-6 Test in Sepsis Patients; Shares Fall |
23-12-27 |
MT |
BJDX: Dynamic Chart
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a rapid, near-patient testing system for triage and monitoring of disease progression. Its product candidate, an IL-6 Test for sepsis triage, is designed to provide results in approximately 20 minutes from sample-to-result to help medical professionals make earlier and better triage/treatment decisions. The Symphony platform is a combination of its intellectual property (IP) and exclusively licensed and patented IP that consists of a mobile device and single-use test cartridges. The Symphony platform and its initial biomarker test, Symphony IL-6 test, is suited to address a subset of the global in vitro diagnostics devices market, including sepsis, cardio-metabolic diseases, cancer and other diseases that require rapid tests. Symphony targets critical care markets where physicians must quickly determine patient acuity to identify optimal treatment regimens.
More about the company
